DRTS ALPHA TAU MEDICAL LTD.

Alpha Tau to Participate in Sidoti Small-Cap Conference

Alpha Tau to Participate in Sidoti Small-Cap Conference

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will present at the Sidoti Small-Cap Virtual Conference on Thursday, December 7th, 2023.

Format:Presentation and 1-on-1 meetings
Date:December 7th, 2023
Time:9:15 AM ET
Location:Virtual
Registration:



About Alpha Tau Medical, Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Investor Relations Contact:

 



EN
29/11/2023

Underlying

DRTSALPHA TAU MEDICAL LTD.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TAU MEDICAL LTD.

 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT®...

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer - Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cance...

February 24, 2026 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the...

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead - Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain - - Ramping U.S. manufacturing for commercial readiness - Jerusalem, Jan. 29, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer th...

January 29, 2026 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Reports New Positive Results in Two Upcoming Presentations a...

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study - Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect - - Alpha DaRT currently being studied together with first-line chemotherapy in U.S. multi-ce...

January 6, 2026 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alph...

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) - Initial module submission marks an important milestone in the pre-market approval process -  - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted - - Module submitted in parallel to execution of ReSTART pivotal study (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy), which is expected to complete recruiting patients in Q1 2026 -...

January 5, 2026 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference - The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones - JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 11:15am PT / ...

December 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch